Zobrazeno 1 - 10 of 365 pro vyhledávání: '"Falcon BL"'
1
Akademický článek
S1PR1 suppresses lung adenocarcinoma progression through p-STAT1/miR-30c-5 p/FOXA1 pathway.
Autor: Chai, Yanfei1,2,3 (AUTHOR), Xiang, Hong1,4 (AUTHOR), Ma, Yuchao2 (AUTHOR), Feng, Wei2 (AUTHOR), Jiang, Zhibin2 (AUTHOR), Zhu, Qianjun2 (AUTHOR), Chen, Yingji2 (AUTHOR), Liu, Quanjun1,4 (AUTHOR), Zhang, Jing1,4 (AUTHOR), Ouyang, Jie1,4 (AUTHOR), Gao, Peng1,4 (AUTHOR), Zhang, Xiao5 (AUTHOR), Chen, Shuhua5 (AUTHOR), Jin, Longyu2 (AUTHOR) jinlongyu1123@163.com, Lu, Hongwei1,4 (AUTHOR) hongweilu@csu.edu.cn
Publikováno v: Journal of Experimental & Clinical Cancer Research (17569966). 11/18/2024, Vol. 43 Issue 1, p1-19. 19p.
Zobrazit plný text záznamu
2
Akademický článek
Targeting sphingosine 1-phosphate and sphingosine kinases in pancreatic cancer: mechanisms and therapeutic potential.
Autor: Limbu, Khem Raj1 (AUTHOR), Chhetri, Rashmi Bhandari1 (AUTHOR), Kim, Subin1 (AUTHOR), Shrestha, Jitendra2 (AUTHOR), Oh, Yoon Sin3 (AUTHOR), Baek, Dong Jae1 (AUTHOR) dbaek@mokpo.ac.kr, Park, Eun-Young1 (AUTHOR) parkey@mokpo.ac.kr
Publikováno v: Cancer Cell International. 10/26/2024, Vol. 24 Issue 1, p1-17. 17p.
Zobrazit plný text záznamu
3
Akademický článek
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies.
Autor: Zheng, Siwei1,2 (AUTHOR), Wang, Wenwen3 (AUTHOR), Shen, Lesang1,2 (AUTHOR), Yao, Yao1,2 (AUTHOR), Xia, Wenjie4 (AUTHOR) xiawenjie1031@zju.edu.cn, Ni, Chao1,2 (AUTHOR) drnichao@zju.edu.cn
Publikováno v: Experimental Hematology & Oncology. 8/6/2024, Vol. 13 Issue 1, p1-33. 33p.
Zobrazit plný text záznamu
4
Akademický článek
Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition.
Autor: Fischl AS; Eli Lilly and Company, Indianapolis, IN., Wang X; Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts., Falcon BL; Eli Lilly and Company, Indianapolis, IN., Almonte-Baldonado R; Eli Lilly and Company, Indianapolis, IN., Bodenmiller D; Eli Lilly and Company, Indianapolis, IN., Evans G; Eli Lilly and Company, Indianapolis, IN., Stewart J; Eli Lilly and Company, Indianapolis, IN., Wilson T; Eli Lilly and Company, Indianapolis, IN., Hipskind P; Eli Lilly and Company, Indianapolis, IN., Manro J; Eli Lilly and Company, Indianapolis, IN., Uhlik MT; Eli Lilly and Company, Indianapolis, IN., Chintharlapalli S; Eli Lilly and Company, Indianapolis, IN., Gerald D; Eli Lilly and Company, Indianapolis, IN., Alsop DC; Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts., Benjamin LE; Eli Lilly and Company, Indianapolis, IN., Bhatt RS; Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. rbhatt@bidmc.harvard.edu.
Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2019 Apr; Vol. 18 (4), pp. 856-867. Date of Electronic Publication: 2019 Feb 20.
Zobrazit plný text záznamu
5
Akademický článek
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
Autor: Konicek BW; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Capen AR; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Credille KM; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Ebert PJ; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Falcon BL; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Heady GL; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Patel BKR; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Peek VL; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Stephens JR; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Stewart JA; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Stout SL; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Timm DE; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Um SL; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Willard MD; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Wulur IH; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Zeng Y; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Wang Y; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Walgren RA; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Betty Yan SC; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
Publikováno v: Oncotarget [Oncotarget] 2018 Feb 13; Vol. 9 (17), pp. 13796-13806. Date of Electronic Publication: 2018 Feb 13 (Print Publication: 2018).
Zobrazit plný text záznamu
6
Akademický článek
The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.
Autor: Lowery CD; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana., VanWye AB; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana., Dowless M; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana., Blosser W; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana., Falcon BL; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana., Stewart J; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana., Stephens J; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana., Beckmann RP; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana., Bence Lin A; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana., Stancato LF; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana. stancato_louis@lilly.com.
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2017 Aug 01; Vol. 23 (15), pp. 4354-4363. Date of Electronic Publication: 2017 Mar 07.
Zobrazit plný text záznamu
7
Akademický článek
A novel nanoemulsion based on clove and thyme essential oils: Characterization, antibacterial, antibiofilm and anticancer activities.
Autor: Hashem, Amr H.1, Doghish, Ahmed S.2,3 ahmed_doghish@azhar.edu.eg, Ismail, Ahmed3, Hassanin, Mahmoud M. H.4, Okla, Mohammad K.5, Saleh, Ibrahim A.6, AbdElgawad, Hamada7, Shehabeldine, Amr M.1 dramrshehab@azhar.edu.eg
Publikováno v: Electronic Journal of Biotechnology. Mar2024, Vol. 68, p20-30. 11p.
Zobrazit plný text záznamu
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
Akademický článek
Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents.
Autor: Falcon BL; Eli Lilly and Company, Indianapolis, IN, USA., Chintharlapalli S; Eli Lilly and Company, Indianapolis, IN, USA., Uhlik MT; Biothera, Eagan, MN, USA., Pytowski B; Eli Lilly and Company, New York, NY, USA. Electronic address: bronek.pytowski@lilly.com.
Publikováno v: Pharmacology & therapeutics [Pharmacol Ther] 2016 Aug; Vol. 164, pp. 204-25. Date of Electronic Publication: 2016 Jun 08.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje